Prospect of Clinical Application of Glypican-3 Targeted Therapy for Hepatocellular Carcinoma

Author: Cheng LI ; Hui-Wen ZHANG ; Peng-Fei HONG
Publication Type:Journal Article
Keywords: chimeric antigen receptor T-cells(CAR-T) immunotherapy; glypican-3(GPC3); hepatocellular carcinoma(HCC); T cell-redirecting antibody; targeted therapy
From: Chinese Journal of Biochemistry and Molecular Biology 2021;37(2):153-160
CountryChina
Language:Chinese
Abstract: Glypican-3 (GPC3) is an oncofetal protein anchored on the plasma membrane and highly expressed in hepatocellular carcinoma (HCC).GPC3 could he used as a biomarker for the diagnosis of HCC and the serum levels of GPC3 in liver cancer patients has a significant role for their prognosis.Moreover, GPC3 in HCC cells is immunoreactive, rendering it a suitable target for the treatment of HCC.Nowadays, several clinical trials targeting GPC3 for HCC therapy have already been conducted: new anti- GPC3 antibodies are generated; the clinical trials about its combination administration with other targeted medicines are being in progress; (tP(3-targeted TRAB, GPC3 vaccines and GPC3-based chimeric antigen receptor T-cells (CAR-T) therapy are under investigation.In this review, we briefly discuss the structure of GPC3, its role in HCC pathogenesis and summarize the recent development in the clinical application of GPC3.We firmly believe that GPC3 would be a promising target for HCC therapy.And further studies focusing on GPC3 should provide us more solid evidence.